Agilent price target lowered to $150 from $170 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Agilent (A) to $150 from $170 and keeps a Buy rating on the shares. The firm cites the company’s below-consensus Q1 earnings and revenue, the analyst tells investors in a research note. Goldman still expects the CAM end market to continue to benefit from strong underlying market trends throughout the year in semiconductors while also staying focused on Agilent’s ability to ramp both LDG – Life Sciences and Diagnostics Markets Group – growth and total company margins throughout the remainder of the year, the firm added.